Experimental drug shows promise for Tough-to-Treat bone cancers

NCT ID NCT02243605

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests the drug cabozantinib in 90 patients with osteosarcoma or Ewing sarcoma that has come back or spread. The drug works by blocking enzymes that help cancer cells grow and by cutting off the blood supply tumors need. Researchers are checking whether the cancer stays stable or shrinks within six months of starting treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cabozantinib (a drug that blocks enzymes needed for cancer cell growth and prevents new blood vessel formation)
What this could lead to: If successful, this could provide a new treatment option for patients whose sarcoma has returned or stopped responding to standard chemotherapy.
What could go wrong: This is a mid-stage trial with only 90 participants, so results may not apply to all patients. The drug may cause side effects and may not shrink tumors or stop progression in everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone osteosarcoma Ewing sarcoma osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC EWING SARCOMA METASTATIC OSTEOSARCOMA RECURRENT EWING SARCOMA RECURRENT OSTEOSARCOMA STAGE III OSTEOSARCOMA AJCC V7 STAGE IV OSTEOSARCOMA AJCC V7 STAGE IVA OSTEOSARCOMA AJCC V7 STAGE IVB OSTEOSARCOMA AJCC V7 UNRESECTABLE EWING SARCOMA UNRESECTABLE OSTEOSARCOMA

Contacts and locations

Locations

CHRU Strasbourg - Hospital Civil

Strasbourg, 67091, France
Center Claudius Regaud

Toulouse, 31052, France
Centre Antoine Lacassagne

Nice, 06189, France
Centre Georges-Francois Leclerc

Dijon, 21079, France
Centre Leon Berard

Lyon, 69373, France
Centre Oscar Lambert

Lille, 59020, France
Gustave Roussy

Villejuif, 94805, France
Hopital De La Timone

Marseille, 13385, France
Institut Bergonie Cancer Center

Bordeaux, 33076, France
Institut Curie Paris

Paris, 75005, France
Institut de Cancerologie de l'Ouest-Rene Gauducheau

Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.